Evidence map›Paper›PMID 27042836›Full record

ArticleBone marrow transplantation2016

Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients.

C Espina, I Jenkins, L Taylor, R Farah, E Cho, J Epworth, K Coleman, J Pinelli, S Mentzer, L Jarrett and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

C EspinaInternal Medicine, University of Washington, Seattle, WA, USA.
I JenkinsClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
L TaylorInternal Medicine, University of Washington, Seattle, WA, USA.
R FarahUPMC Cancer Center, Pittsburgh, PA, USA.
E ChoInternal Medicine, University of Washington, Seattle, WA, USA.
J EpworthInternal Medicine, University of Washington, Seattle, WA, USA.
K ColemanInternal Medicine, University of Washington, Seattle, WA, USA.
J PinelliInternal Medicine, University of Washington, Seattle, WA, USA.
S MentzerInternal Medicine, University of Washington, Seattle, WA, USA.
L JarrettClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
T GooleyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
P O'DonnellInternal Medicine, University of Washington, Seattle, WA, USA.
I B HirschInternal Medicine, University of Washington, Seattle, WA, USA.
M BarInternal Medicine, University of Washington, Seattle, WA, USA.
University of Washington · USFred Hutch Cancer Center · US

Funding

TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
NCI NIH HHS T32 CA009515
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for patients with hematological malignancies. However, is associated with substantial rates of morbidity and mortality. We and others have shown that malglycemia is associated with adverse transplant outcome. Therefore, improving glycemic control may improve transplant outcome. In this prospective study we evaluated the feasibility of using Glucommander (a Computer-Guided Glucose Management System; CGGM) in order to achieve improved glucose control in hospitalized HCT patients. Nineteen adult patients contributed 21 separate instances on CGGM. Patients were on CGGM for a median of 43 h. Median initial blood glucose (BG) on CGGM was 244 mg/dL, and patients on 20 study instances reached the study BG target of 100-140 mg/dL after a median of 6 h. After BG reached the target range, the median average BG level per patient was 124 mg/dL. Six patients had a total of 10 events of BG <70 mg/dL (0.9% of BG measurements), and no patients experienced BG level <40 mg/dL. The total estimated duration of BG <70 mg/dL was 3 h (0.2% of the total CGGM time). In conclusion, our study demonstrates that stringent BG control in HCT patients using CGGM is feasible.

Indexed as

AdultAgedBlood GlucoseDiabetes Mellitus, Type 2Drug Therapy, Computer-AssistedHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansHyperglycemiaInsulinMiddle AgedProspective StudiesTransplant RecipientsYoung AdultBlood GlucoseInsulin

Identifiers

PMID27042836
OpenAlexW2323585542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.